SKANDIA GLOBAL FUNDS PLC - Fidelity Investments

Skandia Global Funds plc
Annual Report and Audited Financial Statements for the year ended 30 June 2012
SIGNIFICANT PURCHASES AND SALES – Skandia Healthcare Fund
Security Description
BUYS
Issue
Currency Shares/Par Cost USD
Pfizer Inc USD 490,600 10,880,374
Abbott Laboratories USD 125,000 7,431,171
Gilead Sciences Inc USD 101,000 5,202,783
Actelion Ltd CHF 114,000 4,619,997
Merck & Co Inc USD 115,700 4,448,944
Sanofi EUR 58,000 4,159,839
Bristol-Myers Squibb Co USD 119,600 3,945,062
Biogen Idec Inc USD 26,900 3,286,732
Onyx Pharmaceuticals Inc USD 72,600 3,084,039
Ono Pharmaceutical Co Ltd JPY 54,000 3,036,593
Express Scripts Holding Co USD 53,540 2,953,997
Life Technologies Corp USD 59,000 2,768,525
HCA Holdings Inc USD 91,900 2,531,723
Biosensors International Group Ltd SGD 2,266,600 2,423,718
Novartis AG CHF 33,000 1,910,177
Questcor Pharmaceuticals Inc USD 53,000 1,898,510
Illumina Inc USD 43,700 1,849,867
Watson Pharmaceuticals Inc USD 26,200 1,644,742
Roche Holding AG CHF 9,000 1,589,891
Mitsubishi Tanabe Pharma Corp JPY 98,500 1,511,165
Thermo Fisher Scientific Inc USD 27,500 1,485,358
Impax Laboratories Inc USD 60,000 1,355,827
China Shineway Pharmaceutical Group Ltd HKD 775,300 1,332,268
Auxilium Pharmaceuticals Inc USD 64,700 1,237,207
OraSure Technologies Inc USD 111,000 1,204,182
Immunogen Inc USD 78,100 1,080,514
Incyte Corp Ltd USD 59,300 1,066,821
UnitedHealth Group Inc USD 19,000 1,024,610
Mediolanum SpA USD 75,700 1,013,685
WellPoint Inc USD 14,000 1,008,764
Baxter International Inc USD 18,500 999,382
249